




# LEGISLATIVE POSITIONS

## Agency Bill Sheet

Patients Rising Now  
700 12th St. NW 700, Suite 700  
Washington, DC 20005  
202-679-8223



Category	PRN's Position	Bill	Title	Summary	Sponsor	Cosponsors	Status
Transparency	Support	S298/HR1829	Pharmacy Benefit Manager Accountability Study Act of 2021	A bill to require the Government Accountability Office to study the role pharmaceutical benefit managers play in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, and for other purposes	Sen. Marsha Blackburn [R-TN] Rep. Diana Harshbarger [R-TN-1]	[1 R (S)] [26 B (H)]	02/08/2021 Introduced in Senate 03/11/2021 Introduced in House
Transparency	Support	HR7995	GOLD CARD Act of 2022	To amend title XVIII of the Social Security Act to exempt qualifying physicians from prior authorization requirements under Medicare Advantage plans, and for other purposes.	Rep. Michael C. Burgess [R-TX-26]	16 B	06/09/2022 Referred to the Committee on Ways and Means, and to the Committee on Energy and Commerce
Access	Support	S4446	Modernizing the Accelerated Approval Pathway Act of 2022	A bill to modernize the process of accelerated approval of a drug for a serious or life-threatening disease or condition.	Sen. Susan Collins [R-ME]	1 D	06/22/2022 Referred to the Committee on Health, Education, Labor, and Pensions
Transparency	Support	S4414	Expose Hospitals Violating Price Transparency Act	A bill to require the Secretary of Health and Human Services to publish a list of hospitals found to be noncompliance with the hospital price transparency rule.	Sen. Mike Braun [R-IN]	0	06/15/2022 Referred to the Committee on Health, Education, Labor, and Pensions
Access	Support	S1645	ADAPT Act	A bill to provide for an accelerated approval pathway for certain drugs that are authorized to be lawfully marketed in other countries	Sen. Mike Braun [R-IN]	0	05/13/2021 Introduced in Senate
Access	Support	S4152	Federal Food, Drug, and Cosmetic Act amendment	A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.	Sen. Mark Kelly [D-AZ]	2 B	05/05/2022 Referred to the Committee on Health, Education, Labor, and Pensions
Access	Support	S4348	FDASLA Act of 2022	A bill to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.	Sen. Patty Murray [D-WA]	1 R	07/13/2022 Placed on Senate Legislative Calendar under General Orders Calendar No 444
Affordability	Support	S4378	Hatch-Waxman Improvement Act of 2022	A bill to reauthorize a provision of the Federal Food, Drug, and Cosmetic Act pertaining to drugs containing single enantiomers.	Sen. Roger Marshall [R-KS]	0	06/13/2022 Referred to the Committee on Health, Education, Labor, and Pensions
Access	Support	HR6973	Enhanced Access to Affordable Medicines Act of 2022	To amend the Federal Food, Drug, and Cosmetic Act to clarify the conditions under which the Secretary of Health and Human Services can approve generic drug applications with labeling temporarily different than the brand name drug, and for other purposes.	Rep. Earl L. "Buddy" Carter [R-GA-1]	1 D	03/09/2022 Referred to the Subcommittee on Health
Transparency	Monitor	HR7140	PROTECTS Act	To amend title XIX of the Social Security Act to increase the ability of Medicare and Medicaid providers to access the National Practitioner Data Bank for the purpose of conducting employee background checks.	Rep. Tom Rice [R-SC-7]	1 D	03/18/2022 Referred to the Subcommittee on Health.

Category	PRN's Position	Bill	Title	Summary	Sponsor	Cosponsors	Status
Access	Monitor	S3991/HR7400	American Made Pharmaceuticals Act of 2022	A bill to direct the Secretary of Health and Human Services to conduct a demonstration program to test providing preferential treatment under the Medicare, Medicaid, and CHIP programs for certain drugs and biologicals manufactured in the United States.	Sen. Tina Smith [D-MN] Rep. Angie Craig [D-MN-2]	[1 R (S & H)]	04/05/2022 Referred to the Committee on Finance (S) 04/06/2022 Referred to the Subcommittee on Health (H)
Transparency	Monitor	HR7377/S1463	Modernizing Therapeutic Equivalence Rating Determination Act	To amend the Federal Food, Drug, and Cosmetic Act to modernize therapeutic equivalence rating determination.	Rep. John R Curtis [R-UT-3] Sen. Bill Cassidy [R-LA]	[1 D (S & H)]	04/05/2022 Referred to the Subcommittee on Health (H) 04/29/2021 Introduced in Senate
Transparency	Monitor	S2837	340B Accountability Act of 2021	A bill to amend the Public Health Service Act to clarify rules relating to drug discounts for covered entities	Sen. Mike Braun [R-IN]	0	09/23/2021 Introduced in Senate
Access	Monitor	HR2831	Prompt Approval of Safe Generic Drugs Act	To amend the Federal Food, Drug, and Cosmetic Act to provide for the prompt approval of drugs when safety information is added to labeling, and for other purposes	Rep. Nanette Diaz Barragan [D-CA-44]	0	04/26/2021 Introduced in House
Access	Monitor	HR5131	Pediatric Access to Critical Healthcare Act	To amend title III of the Public Health Service Act to direct the Secretary of Health and Human Services, acting through the Administrator of the Health Resources and Services Administration, to award grants to eligible entities to carry out construction or modernization projects designed to strengthen and increase capacity within the specialized pediatric health care infrastructure, and for other purposes	Rep. Tony Cardenas [D-CA-29]	19 D	08/31/2021 Introduced in House
Access	Monitor	HR3348	SOS: Sustaining Outpatient Services Act	To amend title XVIII of the Social Security Act to allow payments under the Medicare program for certain items and services furnished by off-campus outpatient departments of a provider to be determined under the prospective payment system for hospital outpatient department services, and for other purposes	Rep. Jim McGovern [D-MA-2]	37 B	05/19/2021 Introduced in House
Access	Monitor	HR6988	Drug Manufacturing Innovation Act of 2022	To amend the Federal Food, Drug, and Cosmetic Act to authorize a program to support the adoption of, and improve the development of, innovative approaches to pharmaceutical product design and manufacturing, and for other purposes.	Rep. Mike Levin [D-CA-49]	1 R	03/09/2022 Referred to the Subcommittee on Health

Category	PRN's Position	Bill	Title	Summary	Sponsor	Cosponsors	Status
Transparency	Monitor	HR4511	FACTS Act	To amend the Federal Food, Drug, and Cosmetic Act to authorize the use of emergency use authorization data and real-world evidence gathered during an emergency to support premarket applications for drugs, biological products, and devices, and for other purposes.	Rep. Michael C. Burgess [R-TX-26]	2 B	07/20/2021 Referred to the Subcommittee on Health
Affordability	Monitor	S2486	Make Taxpayer-Funded Department of Defense Medical Interventions Affordable Act	A bill to authorize the use of drugs, vaccines, and medical technologies to expand military and civilian access to such products and to improve transparency in taxpayer-funded biomedical research investments by the Department of Defense, and for other purposes	Sen. Elizabeth Warren [D-MA]	0	07/27/2021 Introduced in Senate
Affordability	Monitor	S4026	Discounted Drugs for Clinical Trials Act	A bill to amend the Federal Food, Drug, and Cosmetic Act to grant eligible researchers access to eligible products at a discounted price for qualified research, and for other purposes.	Sen. Tina Smith [D-MN]	1 D	04/07/2022 Referred to the Committee on Health, Education, Labor, and Pensions
Affordability	Monitor	HR1790	Fair Indexing for Health Care Affordability Act	To amend the Patient Protection and Affordable Care Act to require the Secretary of Health and Human Services to set forth a method of determining maximum out-of-pocket limits and annual updates to premium tax credit eligibility	Rep. Cynthia Axne [D-IA-3]	6 D	03/11/2021 Introduced in House
Transparency	Monitor	HR6963	Accelerated Approval Integrity Act of 2022	To amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for postapproval studies for drugs approved using accelerated approval, and for other purposes.	Rep. Frank Pallone, Jr. [D-NJ-6]	1 D	03/08/2022 Referred to the Subcommittee on Health
Access	Monitor	S917	Short on Competition Act	A bill to allow for expedited approval of generic prescription drugs and temporary importation of prescription drugs in the case of marginally competitive drug markets and drug shortages	Sen. Amy Klobuchar [D-MN]	3 B	03/23/2021 Introduced in Senate
Access	Monitor	S2910	Expanding Access to Low-Cost Generics Act of 2021	A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period, and for other purposes	Sen. Tina Smith [D-MN]	1 B	09/30/2021 Introduced in Senate
Transparency	Monitor	HR8828	FDA Ethics Act of 2022	To address potential conflicts of interest among entities serving as Food and Drug Administration contractors, and for other purposes	Rep. Ann Kuster [D-NH-2]	0	09/14/2022 Introduced in House